130 related articles for article (PubMed ID: 38580518)
1. Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial.
Pal SK; Grivas P; Gupta S; Dizman N; Zengin Z; Valderrama BP; Rodriguez-Vida A; Roghmann F; Sevillano Fernandez E; Matin SF; Loriot Y; Sridhar SS; Sonpavde G; Fleming MT; Lerner SP; Bellmunt J; Master V; Tripathi A; Davis K; van Veenhuyzen D; Weng R; Daneshmand S
Eur Urol; 2024 Apr; ():. PubMed ID: 38580518
[No Abstract] [Full Text] [Related]
2. Targeting
Pal SK; Somford DM; Grivas P; Sridhar SS; Gupta S; Bellmunt J; Sonpavde G; Fleming MT; Lerner SP; Loriot Y; Hoffman-Censits J; Valderrama BP; Andresen C; Schnabel MJ; Cole S; Daneshmand S
Future Oncol; 2022 Jul; 18(21):2599-2614. PubMed ID: 35608106
[TBL] [Abstract][Full Text] [Related]
3. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
Pal SK; Bajorin D; Dizman N; Hoffman-Censits J; Quinn DI; Petrylak DP; Galsky MD; Vaishampayan U; De Giorgi U; Gupta S; Burris HA; Soifer HS; Li G; Wang H; Dambkowski CL; Moran S; Daneshmand S; Rosenberg JE
Cancer; 2020 Jun; 126(11):2597-2606. PubMed ID: 32208524
[TBL] [Abstract][Full Text] [Related]
4. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.
Lyou Y; Grivas P; Rosenberg JE; Hoffman-Censits J; Quinn DI; P Petrylak D; Galsky M; Vaishampayan U; De Giorgi U; Gupta S; Burris H; Rearden J; Li A; Wang H; Reyes M; Moran S; Daneshmand S; Bajorin D; Pal SK
Eur Urol; 2020 Dec; 78(6):916-924. PubMed ID: 32847703
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations.
Lima NC; Atkinson E; Bunney TD; Katan M; Huang PH
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370101
[TBL] [Abstract][Full Text] [Related]
6. Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma.
Lyou Y; Rosenberg JE; Hoffman-Censits J; Quinn DI; Petrylak D; Galsky M; Vaishampayan U; De Giorgi U; Gupta S; Burris H; Rearden J; Li A; Xu C; Andresen C; Moran S; Daneshmand S; Bajorin D; Pal SK; Grivas P
Clin Genitourin Cancer; 2022 Feb; 20(1):35-42. PubMed ID: 34782263
[TBL] [Abstract][Full Text] [Related]
7. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Lassman AB; Sepúlveda-Sánchez JM; Cloughesy TF; Gil-Gil MJ; Puduvalli VK; Raizer JJ; De Vos FYF; Wen PY; Butowski NA; Clement PMJ; Groves MD; Belda-Iniesta C; Giglio P; Soifer HS; Rowsey S; Xu C; Avogadri F; Wei G; Moran S; Roth P
Clin Cancer Res; 2022 Jun; 28(11):2270-2277. PubMed ID: 35344029
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma.
Sethakorn N; O'Donnell PH
BJU Int; 2016 Nov; 118(5):681-691. PubMed ID: 27271022
[TBL] [Abstract][Full Text] [Related]
9. Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies.
Savarirayan R; De Bergua JM; Arundel P; McDevitt H; Cormier-Daire V; Saraff V; Skae M; Delgado B; Leiva-Gea A; Santos-Simarro F; Salles JP; Nicolino M; Rossi M; Kannu P; Bober MB; Phillips J; Saal H; Harmatz P; Burren C; Gotway G; Cho T; Muslimova E; Weng R; Rogoff D; Hoover-Fong J; Irving M
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221084848. PubMed ID: 35342457
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib.
Yu J; Mahipal A; Kim R
Onco Targets Ther; 2021; 14():5145-5160. PubMed ID: 34720591
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285
[TBL] [Abstract][Full Text] [Related]
13. Molecular grading of tumors of the upper urothelial tract using FGFR3 mutation status identifies patients with favorable prognosis.
Lyle SR; Hsieh CC; Fernandez CA; Shuber AP
Res Rep Urol; 2012; 4():65-9. PubMed ID: 24199183
[TBL] [Abstract][Full Text] [Related]
14. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H
Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245
[TBL] [Abstract][Full Text] [Related]
15. Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.
Bou Zerdan M; Bratslavsky G; Jacob J; Ross J; Huang R; Basnet A
Mol Diagn Ther; 2023 Jul; 27(4):475-485. PubMed ID: 37195586
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
17. Infigratinib, a selective FGFR1-3 tyrosine kinase inhibitor, alters dentoalveolar development at high doses.
Michel ZD; Aitken SF; Glover OD; Alejandro LO; Randazzo D; Dambkowski C; Martin D; Collins MT; Somerman MJ; Chu EY
Dev Dyn; 2023 Dec; 252(12):1428-1448. PubMed ID: 37435833
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
[TBL] [Abstract][Full Text] [Related]
19. Role of FGFR3 in Urothelial Carcinoma.
Akanksha M; Sandhya S
Iran J Pathol; 2019; 14(2):148-155. PubMed ID: 31528172
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma.
Zengin ZB; Chehrazi-Raffle A; Salgia NJ; Muddasani R; Ali S; Meza L; Pal SK
Urol Oncol; 2022 Feb; 40(2):25-36. PubMed ID: 34840077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
